Join to View Full Profile
1717 W Woolbright RdBoynton Beach, FL 33426
Phone+1 561-737-5500
Fax+1 561-737-7055
Dr. Schechter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonResidency, Ophthalmology, 1992 - 1993
SUNY Downstate Health Sciences UniversityResidency, Ophthalmology, 1989 - 1992
Icahn School of Medicine at Mount Sinai/Beth IsraelInternship, Internal Medicine, 1988 - 1989
State University of New York Downstate Medical Center College of MedicineClass of 1988
Certifications & Licensure
FL State Medical License 1992 - 2026
TX State Medical License 1992 - 1993
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia
- Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase Start of enrollment: 2007 Aug 01
- Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Start of enrollment: 2008 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsOptimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review.Barry Schechter, Francis Mah
Ophthalmology and Therapy. 2022-06-01 - Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial.Barry A Schechter, Maitee Urbieta, Jason Bacharach, Melissa Toyos, Robert Smyth-Medina
Clinical Ophthalmology. 2022-01-01 - 4 citationsPhase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.John D. Sheppard, M.T. Bergmann, Barry A. Schechter, Jodi Luchs, Abayomi Ogundele
Clinical Ophthalmology. 2021-01-12
Press Mentions
Dr. David Seamont Joins Florida Eye Microsurgical InstituteMarch 6th, 2025
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
